Validated Targets Sample Clauses
Validated Targets. For the avoidance of doubt, the Parties agree that Theravance's existing programs set forth on Schedule 1.36 are each Discovery Programs directed at Validated Targets.
Validated Targets. 38 Section 7.4. Astra Minimum Efforts. ............................... 38 Section 7.5. Commercialization .................................... 38 Section 7.6. Niche Products ....................................... 39 (iii)
Validated Targets. This Schedule 3.1.5 will be amended by the Parties on or after the date on which any Initial Research Target, Definitive Research Target or Extended Research Target becomes a Validated Target pursuant to Section 3.1.
Validated Targets. During the term of the Research Program and the Astra Development Program, Astra shall use [**] to utilize each Validated Target to discover and develop Hits, Leads, Candidate Drugs and Products. Such efforts [**] in connection with [**] that are at [**] and that are of [**] and [**]. Within thirty (30) days after the end of each calendar half-year during the term of the Research Program and the term of the Astra Development Program, Astra shall provide Millennium with a written report describing Astra's progress in using Validated Targets to discover and develop Hits, Leads, Candidate Drugs and Products. If Astra fails to satisfy its diligence obligations as set forth in this Section 7.3, as agreed between the Parties or determined pursuant to the dispute resolution process as set forth in Section 12.2, with respect to any Validated Target, then Astra's exclusive rights with respect to therapeutic products that are identified through the use of such Validated Target, and the Candidate Gene from which it was derived, [**] (with Millennium, either alone or in collaboration with others) as [**].
Validated Targets. During the term of the Program and the Lilly Development Program, Lilly shall diligently screen the Validated Targets to discover and develop Products. Lilly shall screen all Validated Targets within [**] of the date upon which the Validated Target milestone is paid to Millennium pursuant to Section 8.2. If a Validated Target is not screened within [**] of the payment of the milestone, then Lilly's exclusive right to use said Validated Target in the Field and the area of Oncology shall be converted into a co-exclusive right to use said Validated Target in the Field and the area of Oncology, subject to the other terms of this Section 7.2. Millennium may thereafter screen such a Validated Target in the Field and the area of Oncology, and retain rights to therapeutic leads found by Millennium using such a Validated Target, and proceed with the development of such compound on its own or sublicense the rights to such a compound and [**]. After a Validated Target is first screened, Lilly shall screen said Validated Target at least once every [**]. For each Validated Target, Lilly will be deemed to be diligent under this Section 7.2 so long as Lilly presents a compound arising from a screen against such Validated Target to [**] from the use of the Validated Target in a screen. In the event Lilly does not screen against a specific Validated Target within the time period set forth above, or does not present a compound arising from said screen to [**] within the time specified, Lilly's exclusive right to use said Validated Target in the Field and the area of Oncology shall be converted into a co-exclusive right to use said Validated Target in the Field and the area of Oncology, subject to the other terms of this Section 7.2. Millennium may thereafter screen such a Validated Target in the Field and the area of Oncology, provided, however, that such screening efforts shall be deemed to be a Non-Program Field Project subject to Lilly's rights under Section 5.2, except Lilly's rights thereto shall extend for [**] , Millennium may proceed with the development of such compound on its own or sublicense the rights to such a compound and [**]. Lilly shall not be required to continue to screen a Validated Target [**] from the Program in its development program (defined as a program that has been [**], or its successor) which (i) reacts with said Validated Target or which demonstrates the same clinical utility (and no significant clinical advantages) as a compound which reacts...
Validated Targets. Incyte shall have the right to select up to [**] Initial Validated Targets and up to [**] Supplemental Validated Targets, for a total of up to seven (7) Validated Targets, in the aggregate, in accordance with Section 3.1. Upon selection of seven (7) Validated Targets, in the aggregate, in accordance with Section 3.1, the Option rights granted to Incyte in Section 3.1 shall be deemed to have been exhausted and no further Option rights shall remain in effect (for clarity, regardless of the periods for which Option rights were granted).
Validated Targets